Flow cytometric analyses indicated that induction of epithelial-mesenchymal transition decreased trastuzumab binding, prior to overt loss of HER2 expression in trastuzumab-emtansine-resistant (TDM1R) cells. Kinome analyses of TDM1R cells indicated increased phosphorylation of ErbB1, ErbB4, and FGFR1.
[npj Breast Cancer]
Akhand, S. S., Chen, H., Purdy, S. C., Liu, Z., Anderson, J. C., Willey, C. D., & Wendt, M. K. (2021). Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. Npj Breast Cancer, 7(1), 1–11. https://doi.org/10.1038/s41523-020-00213-5 Cite
0